For the Inventor, By the Inventor

Enter assignee name

Uppsala, Sweden

Orexo Ab

USPTO Granted Patents = 40

% Expired Patents = 32.5

CIPO Patents = 2

EPO Patents = 15

Trademarks = 11

Forward Citations = 202

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Anders Pettersson (15 out of 23 patents)

Andreas Fischer (14 out of 16 patents)

Jonas Sävmarker (10 out of 11 patents)

4. Robert Rönn (10 out of 11 patents)

5. Henri Doods (4 out of 76 patents)

6. Raimund Kuelzer (4 out of 27 patents)

7. Christer Nystrom (4 out of 9 patents)

8. Roland Pfau (4 out of 32 patents)

9. Dirk Stenkamp (4 out of 50 patents)

10. Barbro Johansson (3 out of 3 patents)

11. Emil Schwan (3 out of 3 patents)

12. Henning Priepke (3 out of 47 patents)

13. Klaus Klinder (3 out of 19 patents)

14. Juergen Mack (3 out of 19 patents)

15. Kirsten Arndt (3 out of 29 patents)

Core Competencies:

Pharmaceutical Composition

Opioid Dependence

Drug Delivery

Intranasal Administration

Abuse-Resistant

Alfentanil

Anti-Inflammatory

Gastric Acid Secretion

Insomnia Treatment

Acute Pain

Non-Abusable

40 patents: Sort by Forward Citations

1. 12472154 - Pharmaceutical composition comprising adrenaline (2025-11-18),

2. 12357573 - Pharmaceutical composition for drug delivery (2025-07-15),

3. 12303472 - Pharmaceutical device for use in intranasal administration (2025-05-20),

4. 12268684 - Pharmaceutical composition for nasal delivery (2025-04-08),

5. 12138259 - Method of controlling depression in subjects treated for opioid dependence (2024-11-12),

6. 11986472 - Method of controlling alcohol consumption in subjects treated for opioid dependence (2024-05-21),

7. 11957647 - Pharmaceutical composition comprising adrenaline (2024-04-16),

8. 11883392 - Pharmaceutical composition for nasal delivery (2024-01-30),

9. 11737980 - Pharmaceutical composition for drug delivery (2023-08-29),

10. 11617746 - Method of controlling depression in subjects treated for opioid dependence (2023-04-04),

11. 11433066 - Abuse-resistant pharmaceutical composition for the treatment of opioid dependence (2022-09-06),

12. 11020388 - Abuse-resistant pharmaceutical composition for the treatment of opioid dependence (2021-06-01),

13. 11020387 - Abuse-resistant pharmaceutical composition for the treatment of opioid dependence (2021-06-01),

14. 10946010 - Abuse-resistant pharmaceutical composition for the treatment of opioid dependence (2021-03-16),

15. 10898480 - Pharmaceutical composition for nasal delivery (2021-01-26),

Company Overview

Orexo AB, based in Uppsala, Sweden, specializes in the development of innovative pharmaceutical compositions aimed at addressing critical health issues such as opioid dependence and acute pain management. The company focuses on advanced nasal delivery systems, particularly intranasal administration, to enhance the efficacy and safety of treatments. Orexo is committed to creating abuse-resistant formulations and has made significant strides in developing therapies for insomnia, leveraging its expertise in drug delivery technologies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

40 Patents

#7 in Uppsala

#174 in Sweden

#17,068 in the World

Uppsala, Sweden

Orexo Ab

Forward Citations = 202

24 inventors:

Anders Pettersson (15 out of 23 patents)

Andreas Fischer (14 out of 16 patents)

Jonas Sävmarker (10 out of 11 patents)

4. Robert Rönn (10 out of 11 patents)

5. Henri Doods (4 out of 76 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Orexo Ab. Retrieved from https://idiyas.com/company/orexo-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…